Pyxis Oncology (NASDAQ:PYXS) Announces Quarterly Earnings Results

Pyxis Oncology (NASDAQ:PYXS) announced its quarterly earnings data on Thursday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Trading Up 3.1%

Shares of PYXS stock opened at $1.66 on Friday. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The company’s fifty day simple moving average is $2.51 and its two-hundred day simple moving average is $2.16.

Analyst Upgrades and Downgrades

PYXS has been the subject of a number of research reports. HC Wainwright increased their target price on shares of Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wedbush decreased their price objective on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Friday. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a research note on Thursday. Royal Bank Of Canada upped their target price on Pyxis Oncology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Wells Fargo & Company increased their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.71.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.